-
JAK Inhibitors and Endothelial Cardiovascular Risk
2026-09-21
The reference study compares six JAK inhibitors in cytokine-stimulated human endothelial cells and shows that suppressing IL-6 does not uniformly normalize adhesion, coagulation, or cell-survival responses. Its concentration-aware design provides a useful framework for separating anti-inflammatory activity from vascular effects that may influence cardiovascular risk interpretation.
-
Bazedoxifene and IL-6/GP130 Cancer Signaling
2026-09-21
The 2024 review by Shi and colleagues examines Bazedoxifene, an established selective estrogen receptor modulator, as a repurposing candidate that can inhibit IL-6/GP130 signaling in cancer models. Its analysis connects computational target identification with preclinical evidence for pathway suppression, combination treatment, and further oncology investigation while emphasizing that clinical efficacy remains unestablished.
-
Tofacitinib Citrate: JAK3 Research Workflows
2026-09-20
Tofacitinib citrate enables concentration-aware studies of JAK-STAT signaling, lymphocyte biology, and inflammatory endothelial responses. This guide separates nanomolar immune-cell workflows from higher-concentration vascular stress models, helping researchers choose informative readouts and avoid overinterpreting cytokine suppression.
-
Zosuquidar: ABCB1 Resistance in PROTAC Assays
2026-09-19
Zosuquidar (LY335979) reveals how ABCB1-mediated transport can confound PROTAC efficacy measurements. This article translates recent resistance findings into practical assay-design guidance for multidrug resistance research and targeted protein degradation studies.
-
JNJ-26854165 (Serdemetan) Assay Guide
2026-09-19
A scenario-based guide to using JNJ-26854165 (Serdemetan), SKU A4204, in cell viability, proliferation, apoptosis, migration, and radiosensitization studies. It connects HDM2–p53 biology with practical decisions about endpoint selection, solubility, dose interpretation, and vendor reliability.
-
Rottlerin: A Causal Probe of PKC-Dependent Entry
2026-09-18
Rottlerin is a PKC inhibitor that connects kinase signaling with cancer phenotypes and virus entry biology. This guide explains how to interpret its selectivity, design time-resolved assays, and translate inhibitor results into defensible mechanistic conclusions.
-
Mitochondrial CAT-Tailing in Glioblastoma Growth
2026-09-17
The reference study identifies mitochondrial stress-induced carboxyl-terminal alanine and threonine tailing as a functional ribosome-associated quality-control response that supports glioblastoma survival, migration, and overgrowth. Its experiments connect CAT-tail-dependent remodeling of ATP synthase-associated mitochondrial behavior with membrane-potential maintenance and resistance to apoptosis, providing a mechanistic framework for studying mitochondrial stress in glioblastoma.
-
Lovastatin as a Translational Probe of Cell Fate
2026-09-17
Lovastatin is more than a cholesterol biosynthesis inhibitor: as an HMG-CoA reductase inhibitor, it provides a practical way to interrogate how mevalonate metabolism shapes proliferation, apoptosis, tissue remodeling, and macrophage clearance. This thought-leadership perspective connects those mammalian research applications with the systems-level logic of KNUCKLES-controlled floral meristem termination while clearly defining the evidence and translational limits of that cross-domain comparison.
-
EZ Cap EGFP mRNA 5-moUTP Workflow Guide
2026-09-17
Build more interpretable reporter experiments with a Cap1-capped, 5-moU-modified EGFP transcript designed for stable translation and reduced innate immune recognition. This guide connects cell-based expression assays with nanoparticle delivery, in vivo imaging, and practical troubleshooting.
-
Bazedoxifene Workflows for SERM Research
2026-09-16
Bazedoxifene supports tissue-selective estrogen receptor studies, bone mineral density enhancement models, and an emerging antimalarial repurposing workflow. This practical guide connects formulation, ER pathway assays, parasite-stage analysis, controls, and troubleshooting without conflating preclinical findings with clinical evidence.
-
METTL16–SENP3–LTF Axis in HCC Ferroptosis
2026-09-15
Wang et al. identify a METTL16–SENP3–LTF regulatory axis that protects hepatocellular carcinoma from ferroptosis by reducing the labile iron pool. Their integrated cell, organoid, mouse-model, molecular, and clinical analyses position this pathway as a mechanistic framework for studying ferroptosis resistance and tumor progression.
-
Ibrutinib (PCI-32765) Experimental Workflow
2026-09-15
Build reproducible B-cell receptor signaling inhibition assays with Ibrutinib (PCI-32765), from stock preparation through washout, viability, and pathway readouts. The workflow also explains how findings from ATRX-deficient glioma research can inform assay stratification without overstating evidence for BTK inhibition outside B-cell models.
-
2X HyperFusion High-Fidelity Master Mix Workflow
2026-09-14
Build accurate cloning, construct-verification, and CRISPR assay workflows with a ready-to-use proofreading mix designed for robust amplification. This guide connects high-fidelity PCR decisions to the CD47-targeting nanomedicine study while clearly separating validated product capabilities from practical workflow recommendations.
-
Cell-Surface LAMP1 as a Senescence Marker
2026-09-14
This 2025 Aging Cell study identifies cell-surface LAMP1 as a membrane-accessible marker associated with senescence across human and mouse models, including aging and bleomycin-induced lung fibrosis. Its combination of marker validation, lung-tissue transcriptomics, and a dual antibody–drug conjugate experiment provides a framework for detecting and selectively eliminating senescent cells, while also highlighting the need for further tissue and in vivo validation.
-
Proteostasis as a Translational Oncology Lever
2026-09-13
Bortezomib (PS-341) is more than a cytotoxic benchmark: it is a reversible 20S proteasome inhibitor that can help researchers connect protein turnover, apoptosis, and metabolic state. This article translates recent mitochondrial proteostasis findings into a disciplined framework for oncology experiments without overstating an unproven mechanistic link.